Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib-Reference-Cited by-同舟云学术

Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib

Published:2015-11-04 Issue:1 Volume:172 Page:97-110
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Brümmendorf Tim H.¹²,Cortes Jorge E.³,Khoury Hanna J.⁴,Kantarjian Hagop M.³,Kim Dong‐Wook⁵,Schafhausen Philippe²,Conlan Maureen G.⁶,Shapiro Mark⁷,Turnbull Kathleen⁷,Leip Eric⁷,Gambacorti‐Passerini Carlo⁸,Lipton Jeff H.⁹

Affiliation:

1. Universitätsklinikum RWTH Aachen Aachen Germany

2. Department of Internal Medicine II Hubertus Wald Tumorzentrum University Cancer Centre Hamburg Hamburg Germany

3. University of Texas MD, Anderson Cancer Center Houston TX USA

4. Winship Cancer Institute of Emory University Atlanta GA USA

5. Seoul St. Mary's Hospital Seoul South Korea

6. Pfizer Inc La Jolla CA USA

7. Pfizer Inc Cambridge MA USA

8. University of Milano‐Bicocca Monza Italy

9. Princess Margaret Cancer Centre Toronto ON Canada

Funder

Pfizer

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.13801

Reference31 articles.

1. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

2. Inhibitory effect of imatinib on normal progenitor cells in vitro

3. Nilotinib: A Novel, Selective Tyrosine Kinase Inhibitor

4. Medical Dictionary for Regulatory Activities (MedDRA®)

5. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Critical review of clinical data and expert-based recommendations for the use of bosutinib in the treatment of chronic myeloid leukemia;Frontiers in Oncology;2024-08-26

2. Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study;Annals of Hematology;2023-08-18

3. Imatinib Analogs in Chronic Myeloid Leukemia: a Systematic Qualitative Review;Current Pharmacology Reports;2023-04-10

4. Side effects of treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukaemia and the occurrence of depressive symptoms;Współczesna Onkologia;2023

5. The Role of Bosutinib in Chronic Myeloid Leukemia: An Indian Perspective;Indian Journal of Medical and Paediatric Oncology;2022-11-28